

EVANS AND PARTNERS INVESTOR CONFERENCE

Micro-X to present at 4.20 pm AEDT on 24 March 2021

Adelaide, Australia, 24 March 2021: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for the healthcare and security markets globally, announces that the Company's CEO and Managing Director, Peter Rowland will be presenting at the Evans and Partners Investor Conference at 4.20pm on 24 March 2021 (AEST).

The Evans and Partners Investor Conference is a virtual investor conference which will include presentations from a number of small cap ASX companies. Micro-X CEO, Peter Rowland will provide the attached presentation on the company, followed by a question and answer session.

The E&P Financial Group provides wealth advice to over 9,200 clients with over \$20 billion funds under wealth advice and also has over 180 institutional clients.

This announcement is approved by Kingsley Hall, Company Secretary of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has two mobile digital medical x-ray systems being sold commercially for diagnostic healthcare applications and Micro-X medical products are now in operation in 14 countries around the world.

Micro-X has a portfolio of innovative products in development, including the MBI for imaging Improvised Explosive Devices in security, defence and counter-terrorism applications; a next-generation self-service X-Ray Airport Checkpoint Portal with an integrated body scanner; and a lightweight brain CT imager for early stroke diagnosis in ambulances. Micro-X has its core R&D, engineering and production capability in Adelaide, Australia with a fully in-sourced CNT tube manufacturing line and approximately 95% Australian locally manufactured content.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com

MICRO-X

ACN 153 273 735
ASX: MX1

Evans & Partners
Investor Conference
24 March 2021

Peter Rowland
Managing Director & CEO



ersonal use onl

IMPORTANT NOTICE

DISCLAIMER

SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

NEXT GENERATION X-RAY FOR GLOBAL HEALTH AND SECURITY MARKETS

Platform technology in cold cathode x-ray

- X-ray products with significant reduction in size, weight and power
- **Patented technology** – platform for health and new security applications
- **First to market** with proven cold cathode medical x-ray product

Mobile DR - proven product performance and reliability

- Mobile ultra-lightweight digital x-ray system for bedside imaging
- ‘Nano’ - approved for sale in 40 countries, highly portable and easy to disinfect
- ‘Rover’ - first sales via World Health Organisation in 2020 and first military contract with ADF

IED X-ray Camera - MBI

- DoD funded development to assist with rapid, un-manned bomb and IED assessment
- Major technical breakthrough reduces project time and costs – first prototype by end 2021

Airport Self Service Checkpoint

- Up to **\$5m funding from TSA** to design concept for next generation airport checkpoint for US airports
- Miniature x-ray scanner in automated security portal

CT Brain Scanner - Tomo


- Medical imaging technology for pre-hospital, in-ambulance diagnosis of strokes - treatment within ‘The Golden Hour’
- Up to **\$8m funding** as part of Australian Stroke Alliance’s grant from Medical Research Future Fund



Above: Close up of Rover



Above: Micro-X laboratory in Tonsley facility



Above: Close up of Rover screen

first use only

OUR STRATEGY

MONETISE OUR 'FIRST MOVER' ADVANTAGE

Commercialise high in the value chain to maximise revenue

- avoid commoditisation as long as possible
- **keep innovating to stay in front of competitors**

Look for the 'low hanging fruit' products where our technology delivers a customer benefit and the best product margins

Successful first movers in breakthrough technology move quickly:
early commercial domination becomes a barrier to entry for others

Expand channel partners & collaborations to create required paths to market at scale

OUR GOAL

- Four global production lines:
- **common technology platforms**
 - **high-margin**
 - **operating within five years**

OUR PRODUCTS



Mobile DR

Bedside Imaging – Medical, Military, Vet



IED X-ray Camera

Counter terrorist bomb assessment



Airport Checkpoint

Self-service airport security



Brain CT

In-ambulance stroke imaging

SIGNIFICANT MARKETS ACROSS FOUR PRODUCTION LINES

SEQUENCED PRODUCT ROLLOUT AS CNT MANUFACTURING EXPANDS



MOBILE BEDSIDE DR

2018

First Sales

US\$500M pa*
Addressable Market




IED X-RAY CAMERA

2022*

First Sales

US\$1.8B
Addressable Market




AIRPORT CHECKPOINT

2023*

First Sales

USA: US\$8B
RoW: US\$16B
Addressable Market



BRAIN CT SCANNER

2026*

First Sales

US \$5B
Addressable Market

* Pre COVID-19 levels

* These dates are estimates and may vary

ersonal use only

MOBILE DR: NANO MOBILE X-RAY FOR HEALTHCARE

APPROVED FOR SALE IN 40 COUNTRIES – significant COVID-19 sales demand



Above: Nano being used in The Alfred Hospital, Melbourne



Bedside imaging – hospitals & temporary facilities



Small & portable – 95kg compared to 350-600kg



Approvals – FDA, CE Mark and TGA



Installations in global markets ~ 14 countries



Proven reliability + Positive **customer feedback**



Orders growing - \$4.2m in CY2020



Repeat orders from global clients

\$4.2m

Purchase orders in
CY 2020

14

Countries sold in

\$500m

Addressable market

MOBILE DR: ROVER FOR MILITARY & REMOTE USERS

FIRST CONTRACT FOR ADF - STRONG MILITARY INTEREST & UNMET NEED



Rover is an **adapted version of the Nano** for military use

- Deployed medical facilities treat injured military personnel
- Higher power for trauma use in development
- For use in combat support, disaster relief & humanitarian aid



Unmet need – military currently using small-animal vet X-ray



Limited competition - means higher potential gross margins



FDA Approval - seeking CE mark and TGA approvals



Addressable market in NATO countries ~\$170M

\$1.4m

Sales via WHO in
Oct 2020

\$1.3m

Contract for ADF
Deployable Hospital

FDA

Approved

IED IMAGING CAMERA

BACKSCATTER X-RAY ASSESSMENT OF IEDs VIA ROBOT



Illustration of IED camera in action



Above: IED camera attached to robot



X-Ray camera takes images without separate detector– **one sided viewing**



Bomb disposal technicians face life threatening situation when placing conventional X-ray detector behind target



Australian Defence Force **proof of concept imaging completed**



Customer support - **military and FBI / bomb disposal** interest



New design and architecture – smaller at 22kgs, 30% reduction in COGs, superior resolution and lower development risk



No competition = high gross margins

\$1.8b

Addressable market

Prototype


Target - Dec 2021

2022

Target Launch

AIRPORT SELF-SERVICE CHECKPOINT

US DEPT OF HOMELAND SECURITY - TWO CONTRACTS TOTALLING US\$4M



A blend of backscatter and transmission X-ray to provide **three dimensional imaging of carry on luggage**



Integrated body scanner and passport reader



Based on work Micro-X is undertaking with the UK Government's Department for Transport



Concept reimagines the future of airport checkpoints based on self-service model



~US\$24B global market - USA US\$8B market opportunity

US\$24.0b

Addressable market

US\$4.0m

Two contracts for US
Dept of Homeland
Security

Above: Illustration of Future Airport Checkpoint Portal

MOBILE POINT-OF-CARE DIAGNOSIS - \$8M MRFF FUNDING AWARDED



Illustration of curved ring scanner in ambulance setting



New medical imaging technology for enhanced diagnosis of strokes in a mobile setting - road or air ambulance



Curved detector will be the first of its kind and be built in collaboration with **Fujifilm**



\$8m funding under Second Phase of Australian Stroke Alliance Project – Medical Research Future Fund



Potential to be a game changer in modern stroke management with addressable market ~\$5bn

US\$5.0b

Addressable market

\$8.0m

Australian Stroke Alliance - MRFF funding

Partners

MELBOURNE BRAIN CENTRE



The Royal Melbourne Hospital

FUJIFILM



JOHNS HOPKINS MEDICINE

WORLD-CLASS MANUFACTURING - EFFICIENCIES FROM AUTO INDUSTRY



- State of the art manufacturing facility spanning 2,000m²
 - Adelaide's Tonsley Innovation District
- ISO 13485 certified Quality Management System
- MDR accreditation in progress
- Capacity now 2 units (Nano/Rover) per day
- Local supply chain – heading towards 95% local content with huge reduction in cycle time
- Nano and Rover built on same line with 95% parts commonality

2 Mobile DR
Production capacity a day

0

Warranty claims since
production began



WORLD-CLASS CAPABILITY IN MULTI-DISCIPLINARY SYSTEMS DESIGN



- Customer-led design methodology; proven fast track development process
- 27 engineers and scientists covering: Mechanical & Materials; Electronics & Control; Software & Systems; Vacuum physics; High Voltage engineering; Ergonomics & customer workflow
- Centre of Excellence in software & Image processing being established at Micro-X Inc. in Seattle WA
- 2 key patents granted 2020 plus 1 new patent filing
- In-house, proprietary, image re-construction software algorithms for 3D backscatter and transmission
- TSA contract award recognises systems design, project management & prime contracting capability - not just CNT technology

**CENTRE OF
EXCELLENCE
IN SEATTLE**

Opening in May 2021

**27 ENGINEERS
& SCIENTIST**

IMAGE RECONSTRUCTION & PROCESSING

Personal security

Proprietary imaging software leveraging unique properties of CNT x-ray images


Airport security combines conventional x-ray 3D imaging with backscatter imaging

Brain CT uses cone-beam tomosynthesis image reconstruction algorithms developed in-house


All future programs draw on common image algorithm developments

```
40  
41  
42 $(function(){cards();});  
43 $(window).on('resize', function(){cards();});  
44 function cards(){  
45   var width = $(window).width();  
46   if(width < 750){  
47     cardssmallscreen();  
48   }else{  
49     cardsbigscreen();  
50   }  
51 }  
52 function cardssmallscreen(){  
53   var cards = $('#cards').length;  
54   height = 1;  
55   card2 = 1;  
56 }
```


Core Property Imaging Software and Algorithms



Backscatter Image Reconstruction and Display



Stroke Tomosynthesis Reconstruction and Display



Explosives Imaging CT Reconstruction and Detection

EXPERIENCED LEADERSHIP

TECHNICAL AND COMMERCIAL EXPERTISE TO SUPPORT OUR OBJECTIVES



Peter Rowland
Managing Director & CEO

- › Over 30 years' engineering and management in medical device & and aerospace industries
- › Previously BAE Systems, Ellex Medical and Biolase Technology (NASDAQ)



David Knox
Non-Executive Chairman

- › Extensive international business experience delivering large energy projects
- › Formerly CEO of Santos and Australian Naval Infrastructure
- › Chair of Snowy Hydro, Director of CSIRO



Patrick O'Brien
Non-Executive Director

- › Over 25 years' business and finance experience in UK, Asia and Australia
- › Former Executive Director at Macquarie Group; McKinsey; and Minter Ellison



Yasmin King
Non-Executive Director

- › Extensive experience in business, negotiation & procurement and Government
- › Currently CEO of Skills IQ, formerly Associate Commissioner of ACCC
- › Director of the Australian Healthcare and Hospitals Association



Dr Alexander Gosling, AM
Non-Executive Director

- › Over 40 years' business, technology and R&D experience
- › A founding Director at Invetech (Vision Systems); strategy for Capstone




Jim McDowell
Non-Executive Director

- › Extensive experience in Defence and Aerospace industries
- › Current CEO of Nova Group
- › Former Chief Executive of the Department of Premier for South Australia

GROWTH STAGE COMPANY WITH INSTITUTIONAL SUPPORT

MX1 - Share Trading (1 January 2020 to 17 March 2021)



Share & Trading Statistics (Closing Price on 17 March 2021)

Share Price	\$0.345 per share
Total Shares On Issue	459.5 million
Options Issued	2.5 million
Market Cap	~\$158.6m

Key Financials & Shareholders

Cash	~\$37.5m
Loans	SAFA \$3 million facility
Institutions	~35.6% incl. Perennial (12.0%), Regal (10.7%), Thorney (7.7%)
Board & Related Parties	~ 4.7%

EXPECTED MILESTONES & NEWS FLOW

INITIATIVES TO DELIVER COMMERCIAL OUTCOMES FOR ALL STAKEHOLDERS

ersonal use only

CY 2021

First IED Camera Demonstration

Grow Nano and Rover paths to market

First Rover U.S. Army sale

High Power Generator Complete

Rover Mk II - High Power Launched

Airport Security Contracts Signed

Expansion of Micro-X Inc *(US Operations)*

In-sourcing IED camera tube

BEYOND

Ongoing Nano and Rover Sales

Brain Tomo Prototype

IED Imaging Camera Commercialisation

Airport Security Scanner Prototype

Airport Security Portal Prototype

Adelaide manufacturing IED camera tube

CONCLUSION

UNLOCKING VALUE FROM REVOLUTIONARY COLD CATHODE TECHNOLOGY

- 
- Own the **proven technical edge**
 - Products with **revenues in 26 countries**
 - Multiple product lines** in design
 - Massive addressable markets**
 - Customer pull** – not technology push
 - Demonstrated **design & manufacturing capability** to deliver
 - Continuous **innovation** to **drive value**



MICRO-X

ACN 153 273 735
ASX: MX1

Thank You

Peter Rowland
Managing Director & CEO



ersonal use onl